GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (CHIX:DIAm) » Definitions » Short Interest

Diasorin SpA (CHIX:DIAM) Short Interest


View and export this data going back to 2010. Start your Free Trial

What is Diasorin SpA Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Diasorin SpA's Short Interest

For the Diagnostics & Research subindustry, Diasorin SpA's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diasorin SpA's Short Interest Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Short Interest distribution charts can be found below:

* The bar in red indicates where Diasorin SpA's Short Interest falls into.


;
;

Diasorin SpA Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (CHIX:DIAm) » Definitions » Short Interest
Comparable Companies
TMO DHR XSWX:LONN IDXX A SHSE:603259 IQV MTD NTRA WAT LH DGX XPAR:BIM ILMN XPAR:ERF EXAS RVTY ICLR QGEN MEDP
Traded in Other Exchanges
DSRLF:USA DIA:Italy 0GZX:UK 34D:Germany DIAS:Austria
Address
Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Website
https://www.diasoringroup.com
DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (about 65% of total sales) and molecular diagnostics (about 20%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute about 15% of total sales. DiaSorin's largest market in 2023 was North America, which accounted for 48% of non-covid revenue, followed by Europe (35%) and the Rest of the World (18%).

Diasorin SpA Headlines

No Headlines